Tempus AI (NASDAQ:TEM) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Tempus AI (NASDAQ:TEM) issued its earnings results on Monday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.18), Zacks reports. Tempus AI updated its FY 2025 guidance to EPS.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $69.57 on Tuesday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a 50-day moving average of $50.88 and a 200-day moving average of $52.03. Tempus AI has a 52-week low of $22.89 and a 52-week high of $91.45.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 84,640 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the transaction, the chief executive officer now owns 4,964,820 shares in the company, valued at $401,504,993.40. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jennifer A. Doudna sold 1,320 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $90.00, for a total value of $118,800.00. Following the sale, the director now owns 36,011 shares of the company’s stock, valued at approximately $3,240,990. The trade was a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,583,467 shares of company stock valued at $130,542,311.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TEM shares. Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Bank of America raised their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. cut shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $50.00 to $55.00 in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $59.27.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.